Literature DB >> 8410682

Classification of benzodiazepine hypnotics in humans based on receptor occupancy theory.

K Ito1, Y Yamada, K Nakamura, Y Sawada, T Iga.   

Abstract

Benzodiazepine (BZP) hypnotics are now classified into four groups according to their plasma elimination rates: ultrashort-, short-, intermediate-, and long-acting drugs. Since the specific binding affinities for the BZP receptor vary widely among the BZPs and their active metabolites, it may be more reasonable to correlate their pharmacological activities with the BZP receptor occupancy rather than with their plasma concentrations. The time courses of total plasma concentrations of BZPs and their active metabolites after a single oral administration were obtained from the literature, and their unbound concentrations (Cu) were calculated from the reported values of their plasma unbound fractions. The data of the receptor binding affinities of the BZPs, reported as dissociation constants (Kd) determined by in vitro binding experiments, were also obtained from the literature. Using these values, the time courses of receptor occupancies [Cu/(Kd + Cu) x 100%] were calculated for the various BZPs. A mutual competitive inhibition was considered in the case of the drugs that had active metabolites. Although plasma total and unbound concentration time profiles of the BZPs showed a wide variation, similar patterns were obtained for the time courses of the receptor occupancy among the BZPs in each group, indicating that the BZP hypnotics can be classified more conveniently based on receptor occupancy theory.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8410682     DOI: 10.1007/bf01061774

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  25 in total

1.  Kinetic evaluation for measurement of in vivo receptor occupancy by psychotropic drug in brain: implication for human studies.

Authors:  K Ito; Y Sawada; Y Sugiyama; M Hanano; T Iga
Journal:  Chem Pharm Bull (Tokyo)       Date:  1991-07       Impact factor: 1.645

2.  Kinetic evaluation of pharmacological effects based on allosteric coupling of the benzodiazepine/gamma-aminobutyric acidA receptor in the brain.

Authors:  Y Sawada; K Ito; Y Sugiyama; M Hanano; T Iga
Journal:  Chem Pharm Bull (Tokyo)       Date:  1991-07       Impact factor: 1.645

3.  Comparison of benzodiazepine receptor binding in membranes from human or rat brain.

Authors:  W Sieghart; A Eichinger; P Riederer; K Jellinger
Journal:  Neuropharmacology       Date:  1985-08       Impact factor: 5.250

4.  Plasma binding and transport of diazepam across the blood-brain barrier. No evidence for in vivo enhanced dissociation.

Authors:  R K Dubey; C B McAllister; M Inoue; G R Wilkinson
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

5.  Theoretical structure-activity studies of benzodiazepine analogues. Requirements for receptor affinity and activity.

Authors:  G H Loew; J R Nienow; M Poulsen
Journal:  Mol Pharmacol       Date:  1984-07       Impact factor: 4.436

Review 6.  Clinical pharmacokinetics of nitrazepam.

Authors:  L Kangas; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1981 Sep-Oct       Impact factor: 6.447

7.  Multiple-dose quazepam kinetics.

Authors:  M Chung; J M Hilbert; R P Gural; E Radwanski; S Symchowicz; N Zampaglione
Journal:  Clin Pharmacol Ther       Date:  1984-04       Impact factor: 6.875

8.  Brain receptor binding and lipophilic character of benzodiazepines.

Authors:  P A Borea; A Bonora
Journal:  Biochem Pharmacol       Date:  1983-02-15       Impact factor: 5.858

9.  Kinetics, brain uptake, and receptor binding characteristics of flurazepam and its metabolites.

Authors:  L G Miller; D J Greenblatt; D R Abernethy; H Friedman; M D Luu; S M Paul; R I Shader
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

10.  Triazolam disposition.

Authors:  F S Eberts; Y Philopoulos; L M Reineke; R W Vliek
Journal:  Clin Pharmacol Ther       Date:  1981-01       Impact factor: 6.875

View more
  3 in total

1.  Flavan-3-ol esters: new agents for exploring modulatory sites on GABA(A) receptors.

Authors:  Sebastian P Fernandez; Nasiara Karim; Kenneth N Mewett; Mary Chebib; Graham Ar Johnston; Jane R Hanrahan
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

2.  Prediction of the therapeutic dose for beta-stimulants based on preclinical data: application of oral dosage forms and aerosols to asthmatic patients.

Authors:  K Ito; N Yajima; H Ohtani; Y Yamada; K Nakamura; Y Sawada; T Iga
Journal:  J Pharmacokinet Biopharm       Date:  1993-04

3.  Theory-based analysis of clinical efficacy of triptans using receptor occupancy.

Authors:  Kentaro Tokuoka; Risa Takayanagi; Yuji Suzuki; Masayuki Watanabe; Yasuhisa Kitagawa; Yasuhiko Yamada
Journal:  J Headache Pain       Date:  2014-12-08       Impact factor: 7.277

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.